PARP Inhibitors in the Management of Ovarian Cancer

Publication Date: September 23, 2022

Key Points

Key Points

  • These recommendations pertain only to patients with epithelial ovarian, tubal, or primary peritoneal cancer who have not previously received a poly(ADP-ribose) polymerase inhibitors (PARPi).
  • The recommendations are based on clinical trial results and FDA approvals and do not necessarily capture regulatory approvals in other jurisdictions.

Treatment

...Treatment...

...Repeati...

Recommendation 1.0Repeating PARPi therapy in the...


Newly Di...

...2.0PARPi are NOT recommended for use in initial...

...Recommendation 2.1Patients with ne...

...commendation 2.2The addition of olaparib to bev...

...on 2.3Inclusion of the PARPi, veliparib,...


...Re...

...pid Update – Recommendation 3.0

...Pi monotherapy maintenance (second-line...

...ance treatment with niraparib for patients...

...te – Recommendation 3.1/3.2PARPi monother...

...date – Recommendation 3.3PARPi monotherapy is NO...


...PARPi...

...on 4.0PARPi are NOT recommended for us...


...Manage...

...ecommendation 5.0 Anemi...

...ients requiring a blood transfusion for symp...

...ents with progressive anemia may be offered g...

...ation 5.1 Neutropenia:

...th factor is NOT indicated for use...

...tropenia (grade 4 lasting at least 5–7 d...

...endation 5.2 Platelets:...

...penia is most common with niraparib. Nirapar...

...Discontinue PARPi for persistent thromboc...

...ion 5.3 Persistent cytopenia:Evaluation for trea...

...ecommendation 5.4 Na...

a. Many patients will have tachyphylaxi...

.... Persistent nausea requiring daily anti-emeti...


...1. PARP Inhibitors in the Management of Ovarian C...


...PARPi Use Opportunities in PARPi-Naïve Women...